EGRX - EGRX Investor Alert: Kaplan Fox & Kilsheimer LLP Investigates Eagle Pharmaceuticals Inc. (Nasdaq: EGRX) | Benzinga

NEW YORK, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP is investigating potential claims on behalf of investors who purchased securities of Woodcliff Lake, New Jersey-based Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) ("Eagle" or the "Company"). Click Here to Join Investigation.

If you purchased Eagle securities and would like to discuss our investigation, your rights, or your interests please click here. You may also contact us by emailing jcampisi@kaplanfox.com or calling (212) 329-8571.

On November 9, 2023, Eagle issued a press release stating that "it will be delaying the release of its third quarter 2023 results and investor conference call, previously scheduled for today . . . . The Company requires more time to review potential adjustments relating to the reporting of sales of PEMFEXY® prior to filing its Form 10-Q. In addition, the Company expects to revise its previously disclosed 2023 full year guidance downward."

EGRX)>Full story available on Benzinga.com